Background: To explore the postoperative prognosis of esophageal squamous cell carcinoma (ESCC) patients with stage IB/IIA, using a prognostic score (PS).
Methods: Stage IB/IIA ESCC patients who underwent esophagectomy from 1999 to 2010 were included. We retrospectively recruited 153 patients and extracted their medical records. Moreover, we analyzed the programmed death ligand-1 (PD-L1) expression of their paraffin tissue. The cohort were randomly divided into a training group (N = 123) and a validation group (N = 30). We selected overall survival (OS) as observed endpoint. Prognostic factors with a multivariable two-sided P < 0.05 met standard of covariate inclusion.
Results: Univariable and multivariable analyses identified pTNM stage, the number of lymph nodes (NLNs) and PD-L1 expression as independent OS predictors. Primary prognostic score which comprised above three covariates adversely related with OS in two cohorts. PS discrimination of OS was comparable between the training and internal validation cohorts (C-index = 0.774 and 0.801, respectively). In addition, the PS system had an advantage over pTNM stage in the identification of high-risk patients (C-index = 0.774 vs. C-index = 0.570, P < 0.001). Based on PS cutoff, training and validation datasets generated low-risk and high-risk groups with different OS. Our three-factor PS predicted OS (low-risk subgroup vs. high-risk subgroup 60-month OS, 74% vs. 23% for training cohort and 83% vs. 45% for validation cohort).
Conclusion: Our study suggested a PS for significant clinical stratification of IB/IIA ESCC to screen out subgroups with poor prognosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876804 | PMC |
| http://dx.doi.org/10.1186/s12876-021-01636-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Delineation of reduced CTV2 on the basis of the characteristics and distribution of cervical lymph node metastasis in nasopharyngeal carcinoma.
BMC Cancer
January 2025
Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, 650032, P. R. China.
Introduction: The core objective of this study was to precisely locate metastatic lymph nodes, identify potential areas in nasopharyngeal carcinoma patients that may not require radiotherapy, and propose a hypothesis for reduced target volume radiotherapy on the basis of these findings. Ultimately, we reassessed the differences in dosimetry of organs at risk (OARs) between reduced target volume (reduced CTV2) radiotherapy and standard radiotherapy.
Methods And Materials: A total of 209 patients participated in the study.
Phase I-II study of prone hypofractionated accelerated breast and nodal intensity modulated radiation therapy.
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiation Oncology, New York University Langone Health and Perlmutter Cancer Center, New York, NY.
Background: In patients with breast cancer, prone radiation therapy (RT) has been shown to reduce heart and lung dose. Though prone positioning is routinely used for whole breast RT, its use when treating the regional lymph nodes (RLNs) is not widespread.
Methods: In this phase I-II trial for stage IB-IIA breast cancer treated with lumpectomy or mastectomy, patients received 40.
First study on the efficiency of Tc-rituximab for sentinel lymph node mapping and biopsy in oral squamous cell carcinoma.
Ann Nucl Med
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Objective: To explore the clinical efficiency of using the sentinel lymph node (SLN) imaging agent Tc-rituximab for lymphoscintigraphy and SLN biopsy (SLNB) in oral squamous cell carcinoma (OSCC) patients.
Methods: A retrospective study was conducted on 23 patients with OSCC who underwent Tc-rituximab lymphoscintigraphy and SLNB. The cohort comprised 16 men (69.
Prognostic markers could extend adjuvant immunotherapy to high-risk stage IB/IIA melanoma: A modeling study.
JAAD Int
February 2025
Frazer Institute, Dermatology Research Centre, Experimental Dermatology Group, The University of Queensland, Brisbane, Australia.
RNA sequencing and multiplexed immunohistochemistry reveal the factors for postoperative recurrence of stage IB-IIA cervical squamous cell carcinoma.
Discov Oncol
September 2024
Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510150, China.
Article Synopsis
- The study aimed to identify predictive biomarkers for tumor recurrence in Stage IB-IIA Cervical Squamous Cell Carcinoma (CSCC) after surgical treatment by analyzing differences between recurrence and non-recurrence patients.
- Researchers utilized mRNA sequencing and multiplexed immunohistochemistry on patients followed for about three years.
- Key findings suggested that certain gene expressions, activation of specific pathways, and immune cell characteristics may indicate a higher risk of recurrence, providing potential targets for future treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!